Home / Restatements / ABVC BIOPHARMA, INC.
Filed 2026-03-03 路 Form 8-K 路 Accession 0001213900-26-023054 nano
Price before filing: $1.48 (2026-03-02 close, split/dividend-adjusted)
Market cap at flag: $35.2M (2026-03-03) 路 Latest: $23.9M (2026-10-16)
| Window | ABVC | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -26.4% | -4.2% | -22.2% | 2026-04-02 |
| 90 days | -8.1% | +10.8% | -18.9% | 2026-06-01 |
| 180 days | -42.1% | +12.3% | -54.4% | 2026-08-31 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"(the " Company "), after discussion with management and in consultation with the Company's independent registered public accounting firm, concluded that the financial statements for the quarterly period ended September 30, 2025 (the " Restated Period "), as included in the Company's Quarterly Report on Form 10-Q for the respective periods (the " Prior Filing "), should no longer be relied upon due to errors in those..."
Quoted from the filing. Source
The company says previously issued financial statements should no longer be relied upon (8-K Item 4.02). This is one of the most serious accounting red flags: past reported numbers were wrong and will be restated.
Why this score: also within 90 days: Going-concern doubt
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.